Valion Bio, Inc. — Form SCHEDULE 13D/A
Filed August 27, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 52/100
What the filing says
3i, LP acquired 132,702 shares of Valion Bio common stock on August 25, 2026, at $0.1574 per share, for a total investment of approximately $20,886. This purchase is disclosed in a Schedule 13D/A amendment and represents a transaction in the past 60 days outside those previously reported in the original Schedule 13D filing.
Why this rating
~$21K purchase is ~0.5% of $4M market cap—modest but non-trivial stake accumulation. Neutral: no strategic detail, control implication, or business impact disclosed.
See more from August 27, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.